| Name | Title | Contact Details |
|---|
RethinkFirst aims to provide enterprises, families, educators, payors, and behavioral healthcare providers affordable, best practice treatment solutions for children with special needs. Rethink is unique in our foot-print offering clinical support, best-practice tools, and research-based content via technology to all market segments, reaching more children with special needs than any other solution. Our platforms support curriculum planning, professional development, parent training, and tracking of progress. Through video and online tools, we bring to life best practice teaching, treatment, and intervention strategies that help educators, parents, and clinicians personalize instruction for every child. Rethink`s award-winning solutions are currently being used by employers, the US Department of Defense, Managed Care, Medicaid, federal, state and social service agencies, public school districts, and families nation- and worldwide.
Impira offers a Digital Asset Intelligence platform for any enterprise. Built with artificial intelligence technology, Impira`s platform eliminates manual, repetitive workflows traditionally needed to manage digital assets.
Salucro provides technology that makes it easier to collect patient payments, while providing patients with the best financial experience possible.
Providing a file-centric approach to your data security and privacy needs to protect intellectual property and meet regulatory compliance
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.